SMYD2 and metabolic dysfunction-associated steatohepatitis: RNA-sequencing further disclosed altered hepatic gene expression profiles, which partly overlapped in the liver of these knockout mice, especially in lipid metabolism, inflammation and fibrosis pathways.1 Finally, to verify the therapeutic potential of these newly discovered NASH genes, the authors tested the effect of AZ505, a selective SMYD2 inhibitor, in the western diet mouse model.